NASDAQ:BLUE bluebird bio (BLUE) Stock Forecast, Price & News $3.76 +0.04 (+1.08%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$3.65▼$3.7950-Day Range$2.79▼$5.0352-Week Range$2.78▼$8.58Volume3.65 million shsAverage Volume4.28 million shsMarket Capitalization$400.10 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media bluebird bio MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside86.2% Upside$7.00 Price TargetShort InterestBearish22.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 9 Articles This WeekInsider TradingSelling Shares$14,455 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.13) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector263rd out of 981 stocksBiological Products, Except Diagnostic Industry35th out of 163 stocks 4.1 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, bluebird bio has a forecasted upside of 86.2% from its current price of $3.76.Amount of Analyst Coveragebluebird bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted22.07% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in bluebird bio has recently decreased by 0.25%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 2.4 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for bluebird bio this week, compared to 6 articles on an average week.Search InterestOnly 19 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat Follows9 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,455.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions79.01% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($2.13) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About bluebird bio (NASDAQ:BLUE) Stockbluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.Read More Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News HeadlinesJune 8, 2023 | bizjournals.comBIO speakers underscore 'crucial' moment for genetic medicinesJune 7, 2023 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Insider Thomas J. Klima Sells 4,130 Shares of StockJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 7, 2023 | americanbankingnews.combluebird bio Sees Unusually Large Options Volume (NASDAQ:BLUE)June 3, 2023 | americanbankingnews.comBarclays Upgrades bluebird bio (NASDAQ:BLUE) to OverweightJune 2, 2023 | proactiveinvestors.comBaird analysts unfazed by bluebird bio short sellersJune 2, 2023 | proactiveinvestors.combluebird bio shortseller attack leaves analysts unfazedJune 1, 2023 | msn.comBarclays Upgrades Bluebird bio (BLUE)June 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for bluebird bioJune 1, 2023 | markets.businessinsider.comPositive Report for Bluebird Bio (BLUE) from BarclaysJune 1, 2023 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of "Hold" by BrokeragesMay 20, 2023 | americanbankingnews.comHead-To-Head Review: bluebird bio (NASDAQ:BLUE) vs. Brickell Biotech (NASDAQ:BBI)May 18, 2023 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comMay 15, 2023 | markets.businessinsider.comVor Biopharma (VOR) Receives a Buy from Robert W. BairdMay 14, 2023 | americanbankingnews.comFY2023 EPS Estimates for bluebird bio, Inc. (NASDAQ:BLUE) Raised by William BlairMay 14, 2023 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) to Post Q2 2023 Earnings of ($0.69) Per Share, Wedbush ForecastsMay 12, 2023 | bloomberg.comEU payment fight could cut 40% from gene therapy salesMay 12, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Bluebird Bio (BLUE)May 11, 2023 | marketwatch.comSickle Cell Disease Treatment Market Size, Global Industry Outlook, Detailed Analysis and Forecast 2023-2030May 11, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Bluebird Bio (BLUE)May 10, 2023 | uk.finance.yahoo.combluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, SkysonaMay 10, 2023 | finance.yahoo.comWill bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely?May 9, 2023 | finance.yahoo.comBluebird Bio (BLUE) Q1 Earnings Surpass EstimatesMay 9, 2023 | msn.combluebird bio surges 14% on Q1 results, sickle cell candidateMay 8, 2023 | markets.businessinsider.comWhat Wall Street expects from bluebird bio's earningsMay 8, 2023 | msn.combluebird bio Q1 2023 Earnings PreviewSee More Headlines BLUE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees518Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+86.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-3,054.45% Pretax Margin-3,051.55% Return on Equity-52.40% Return on Assets-19.92% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.00 Sales & Book Value Annual Sales$3.60 million Price / Sales110.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book1.58Miscellaneous Outstanding Shares106,410,000Free Float104,177,000Market Cap$399.04 million OptionableOptionable Beta0.89 Key ExecutivesNick LeschlyDirectorAndrew ObenshainPresident, Chief Executive Officer & DirectorThomas J. KlimaChief Operating & Commercial OfficerChristopher Stanley KrawtschukChief Financial OfficerRichard ColvinChief Medical OfficerKey CompetitorsIcosavaxNASDAQ:ICVXCabaletta BioNASDAQ:CABAHumacyteNASDAQ:HUMACoherus BioSciencesNASDAQ:CHRSOmega TherapeuticsNASDAQ:OMGAView All CompetitorsInsiders & InstitutionsThomas J KlimaSold 4,130 sharesTotal: $14,455.00 ($3.50/share)Prelude Capital Management LLCBought 26,653 shares on 6/1/2023Ownership: 0.025%Ameriprise Financial Inc.Bought 26,751 shares on 5/22/2023Ownership: 0.073%JPMorgan Chase & Co.Sold 48,079 shares on 5/18/2023Ownership: 1.170%New York State Common Retirement FundSold 12,063 shares on 5/18/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions BLUE Stock - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price forecast for 2023? 10 Wall Street analysts have issued 1-year target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 86.7% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2023? bluebird bio's stock was trading at $6.92 at the beginning of the year. Since then, BLUE stock has decreased by 45.8% and is now trading at $3.75. View the best growth stocks for 2023 here. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) posted its earnings results on Tuesday, May, 9th. The biotechnology company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.75. The biotechnology company earned $2.40 million during the quarter, compared to analyst estimates of $26.97 million. bluebird bio had a negative net margin of 3,054.45% and a negative trailing twelve-month return on equity of 52.40%. bluebird bio's revenue for the quarter was up 26.3% on a year-over-year basis. During the same period last year, the company posted ($1.66) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Horizon Kinetics Medical ETF (MEDX), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco DWA SmallCap Momentum ETF (DWAS). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." Who are bluebird bio's major shareholders? bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (16.70%), BlackRock Inc. (8.41%), Pictet Asset Management SA (2.92%), Dimensional Fund Advisors LP (2.44%), Geode Capital Management LLC (1.97%) and Bank of America Corp DE (1.85%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $3.75. How much money does bluebird bio make? bluebird bio (NASDAQ:BLUE) has a market capitalization of $399.04 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How many employees does bluebird bio have? The company employs 518 workers across the globe. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com. This page (NASDAQ:BLUE) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.